UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Important steps in the journey to highly effective CFTR modulator access for people with CF

Journal of cystic fibrosis, 2019-09, Vol.18 (5), p.577-578

2019

Volltextzugriff (PDF)

WS23.4 IV antibiotic treatment of <9 days and treatment at home for CF pulmonary exacerbation are associated with increased odds of IV retreatment within 30 days

Journal of cystic fibrosis, 2016-06, Vol.15, p.S35-S35

2016

Volltextzugriff (PDF)

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

Journal of cystic fibrosis, 2016-06, Vol.15, p.S60-S61

2016

Volltextzugriff (PDF)

311 Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis

Journal of cystic fibrosis, 2015-06, Vol.14, p.S138-S138

2015

Volltextzugriff (PDF)

EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin

Journal of cystic fibrosis, 2017-06, Vol.16, p.S54-S54

2017

Volltextzugriff (PDF)

WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009

Journal of cystic fibrosis, 2013-06, Vol.12, p.S24-S24

2013

Volltextzugriff (PDF)

38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin

Journal of cystic fibrosis, 2016-06, Vol.15, p.S61-S61

2016

Volltextzugriff (PDF)

186 Manifestation and progression of illness in young children with cystic fibrosis: A targeted literature review

Journal of cystic fibrosis, 2015-06, Vol.14, p.S105-S105

2015

Volltextzugriff (PDF)

117 Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis clinical trials

Journal of cystic fibrosis, 2015-06, Vol.14, p.S87-S87

2015

Volltextzugriff (PDF)

WS7.6 Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center

Journal of cystic fibrosis, 2014-06, Vol.13, p.S16-S16

2014

Volltextzugriff (PDF)

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint

Journal of cystic fibrosis, 2010-09, Vol.9 (5), p.332-338

2010

Volltextzugriff (PDF)

189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response

Journal of cystic fibrosis, 2015-06, Vol.14, p.S106-S106

2015

Volltextzugriff (PDF)

188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations

Journal of cystic fibrosis, 2015-06, Vol.14, p.S106-S106

2015

Volltextzugriff (PDF)

WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations

Journal of cystic fibrosis, 2015-06, Vol.14, p.S13-S13

2015

Volltextzugriff (PDF)

WS3.4 Lack of correlation between sputum Pseudomonas aeruginosa density and FEV1 changes among CF patients treated with inhaled antibiotics

Journal of cystic fibrosis, 2014-06, Vol.13, p.S6-S6

2014

Volltextzugriff (PDF)

Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis

Trends in molecular medicine, 2020-12, Vol.26 (12), p.1068-1077

2020

Volltextzugriff (PDF)

WS24.5 Unresponsive patients benefit from switching intravenous antibiotic treatments for pulmonary exacerbation

Journal of cystic fibrosis, 2012-06, Vol.11, p.S54-S54

2012

Volltextzugriff (PDF)

337 Changing incidence and thresholds for pulmonary exacerbation treatment, North America 1995-2005

Journal of cystic fibrosis, 2012-06, Vol.11, p.S143-S143

2012

Volltextzugriff (PDF)

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact

Journal of cystic fibrosis, 2024-01, Vol.23 (1), p.58-64

2024

Volltextzugriff (PDF)

180 Choice of IV vs. non-IV antibiotics for treating pulmonary exacerbations in patients with cystic fibrosis

Journal of cystic fibrosis, 2012-06, Vol.11, p.S102-S102

2012

Volltextzugriff (PDF)

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

Journal of cystic fibrosis, 2020-07, Vol.19 (4), p.595-601

2020

Volltextzugriff (PDF)

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

Journal of cystic fibrosis, 2018-07, Vol.17 (4), p.484-491

2018

Volltextzugriff (PDF)

Sample size estimation for CF clinical trials using rate of lung function decline (RLFD) as an efficacy endpoint

Journal of cystic fibrosis, 2008-06, Vol.7, p.S64-S64

2008

Volltextzugriff (PDF)

WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management

Journal of cystic fibrosis, 2022-06, Vol.21, p.S1

2022

Volltextzugriff (PDF)

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis

Journal of cystic fibrosis, 2024-07, Vol.23 (4), p.676-684

2024

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Important steps in the journey to highly effective CFTR modulator access for people with CF

WS23.4 IV antibiotic treatment of <9 days and treatment at home for CF pulmonary exacerbation are associated with increased odds of IV retreatment within 30 days

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

311 Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis

EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin

WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009

38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin

186 Manifestation and progression of illness in young children with cystic fibrosis: A targeted literature review

117 Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis clinical trials

WS7.6 Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint

189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response

188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations

WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations

WS3.4 Lack of correlation between sputum Pseudomonas aeruginosa density and FEV1 changes among CF patients treated with inhaled antibiotics

Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis

WS24.5 Unresponsive patients benefit from switching intravenous antibiotic treatments for pulmonary exacerbation

337 Changing incidence and thresholds for pulmonary exacerbation treatment, North America 1995-2005

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact

180 Choice of IV vs. non-IV antibiotics for treating pulmonary exacerbations in patients with cystic fibrosis

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

Sample size estimation for CF clinical trials using rate of lung function decline (RLFD) as an efficacy endpoint

WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis

Aktive Filter

Suchergebnisse filtern